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INTRODUCTION
A recent multicenter phase III clinical trial randomly
assigned recipients of HLA-identical sibling bone marrow
transplants to tacrolimus-based or cyclosporine-based
immunosuppression to prevent acute GVHD. Randomiza-
tion was stratified at each center based on age and donor
alloimmunization status at the time of enrollment. Unex-
pectedly, the stratified randomization assigned more patients
with advanced-stage disease to the tacrolimus group (n=68;
41%) than to the cyclosporine group (n=48; 29%, p = 0.023,
x2 test) [1]. When 2-year survival rates were examined, no
significant difference was seen between treatment arms
among patients with nonadvanced disease (62% tacrolimus
arm vs. 64% cyclosporine arm), but among patients with
advanced disease, 2-year survival was 25% in the tacrolimus
arm and 42% in the cyclosporine arm (p < 0.01, Wilcoxon
test for equality of survival curves). 
The difference in survival between patients with
advanced-stage disease receiving cyclosporine vs. those with
advanced-stage disease receiving tacrolimus was unexpected.
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ABSTRACT
A phase III comparative trial of tacrolimus- vs. cyclosporine-based graft-vs.-host disease (GVHD) prophylaxis for
human leukocyte antigen (HLA)-identical sibling bone marrow transplantation showed less GVHD but poorer sur-
vival in the tacrolimus arm. To test the comparability of the two treatment arms with respect to baseline survival
prognosis, a matched control study using exclusively cyclosporine-treated patients from the International Bone
Marrow Transplant Registry (IBMTR) database was performed. Controls were matched (2:1) based on age (within 5
years), disease, and pretransplant disease status. Two-year survival for tacrolimus-treated clinical trial patients was
similar to that of their cyclosporine-treated matched controls (27 and 24%, respectively), and 2-year survival of the
cyclosporine-treated clinical trial patients was similar to that of their cyclosporine-treated matched IBMTR controls
(42 and 45%, respectively). Consistent with the clinical trial results, the cyclosporine-treated IBMTR controls
matched to the tacrolimus group had significantly poorer 2-year survival than the cyclosporine-treated IBMTR con-
trols matched to the cyclosporine group (24 and 45%, respectively; p < 0.01). No significant difference was seen in
GVHD between the cyclosporine-treated clinical trial patients and their matched controls; however, the tacrolimus-
treated clinical trial patients had significantly less GVHD than their cyclosporine-treated IBMTR controls (p <
0.01). These results support the hypothesis that the survival difference in the phase III trial resulted from an imbal-
ance in the underlying risk factors for death in the two groups rather than from the randomized immunosuppressive
regimen. 
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Results of several previous trials demonstrated the effective-
ness of tacrolimus for the prevention of GVHD without
suggesting any survival disadvantage [2–7]. Given the het-
erogeneity of patients with advanced-stage malignancies, we
hypothesized that the difference in survival was caused by an
imbalance in the randomization of patients with poor prog-
nosis. However, although multivariate analyses were per-
formed using selected baseline/transplant factors as covari-
ates, it was not possible to include all disease diagnosis and
disease status (remission vs. relapse and number) combina-
tions in a model. Determining the expected survival patterns
of a similar population from the published literature also
was not feasible because the advanced-disease population in
this trial was a unique group with respect to such factors as
diagnosis and stage of disease (i.e., remission or relapse sta-
tus). Therefore, we performed a matched control study
using exclusively cyclosporine-treated controls obtained
from the International Bone Marrow Transplant Registry
(IBMTR) [8].
MATERIALS AND METHODS
Clinical trial
The randomized (1:1), open-label, comparative prospec-
tive study, conducted between May 1993 and December
1996, involved 329 adults (‡ 12 years of age) receiving allo-
geneic bone marrow transplants for treatment of malignan-
cies. Eligible patients were scheduled for a primary, non–T-
depleted bone marrow transplant from a genotypically
HLA-identical sibling donor. Patients were required to have
a serum creatinine level <3.0 mg/dL. Within each center,
patients were stratified with respect to patient age (<40 years
or ‡ 40 years) and donor/recipient sex match (alloimmunized
female donor to male recipient or not). Details of the trial
are published [1]. On the day before marrow transplanta-
tion, patients received either tacrolimus (Prograf, FK506;
0.03 mg/kg per 24 hours) or cyclosporine (3 mg/kg per 24
hours) as a continuous intravenous infusion. Patients in both
treatment arms received a standard short-course methotrex-
ate regimen.
A total of 116 of the 329 randomized patients had
advanced-stage disease, prospectively defined to include
patients whose underlying hematologic malignancy was
uncontrolled (relapse or never in remission) at the time of
transplantation or who had a type of malignancy that, his-
torically, was associated with poor survival after allogeneic
bone marrow transplantation (e.g., multiple myeloma,
chronic lymphocytic leukemia). These 116 patients consti-
tute the study group for this analysis. 
IBMTR selection of controls
The database for advanced-stage disease patients in both
arms of the phase III trial was provided to the IBMTR by
the trial sponsor. An attempt was made to identify two con-
trols for each of the 116 trial patients from among patients
in the IBMTR database receiving an HLA-identical sibling
donor bone marrow transplant in a North American center
during a corresponding time frame (1990–1995). Because
we wished to test the impact of disease status on survival
without confounding by the GVHD prophylaxis regimen,
all control patients received a cyclosporine-methotrexate
regimen for GVHD prophylaxis. To avoid overlap, registry
patients with date of birth, sex, and transplant date identical
to those of any clinical trial participant were excluded. Table
1 shows the series of selection factors applied to define the
database of 879 patients from which matched controls were
selected. Matching criteria were diagnosis, pretransplant
disease status, and age (within 5 years). If more than two
controls were available for a patient, two were selected at
random. 
IBMTR vs. trial population comparisons
The clinical trial included a 2-year follow-up period;
minimum follow-up for IBMTR control patients was 210
days. Advanced-disease patients were evaluated with respect
to 2-year survival and incidence of grades II to IV acute
GVHD within 100 days posttransplant. GVHD was graded
according to standard criteria [9] in both the clinical trial and
the IBMTR analysis. The following comparisons were made:
1) all patients (tacrolimus-treated and cyclosporine-
treated) in the phase III clinical trial (clinical trial patients)
vs. their cyclosporine-treated controls selected from the
IBMTR database (cyclosporine-treated, matched IBMTR
controls);
2) tacrolimus-treated clinical trial patients vs. their
cyclosporine-treated matched IBMTR controls (cyclo-
sporine-treated, tacrolimus-matched IBMTR controls);
3) cyclosporine-treated clinical trial patients vs. their
cyclosporine-treated, matched IBMTR controls (cyclo-
sporine-treated, cyclosporine-matched IBMTR controls); and
4) cyclosporine-treated IBMTR controls matched to
patients on the tacrolimus arm of the clinical trial vs. cyclo-
sporine-treated IBMTR controls matched to patients on the
cyclosporine arm of the clinical trial.
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Statistical methods
Cox proportional hazards regression analysis stratified
on matched pairs [10] was used to compare the survival
probability and acute GVHD rate between clinical trial
patients and matched IBMTR controls, and between cyclo-
sporine-treated, tacrolimus-matched IBMTR controls and
cyclosporine-treated, cyclosporine-matched IBMTR con-
trols. Additional variables examined include donor-patient
sex match (male to male, male to female, female to male,
and female to female), donor and patient cytomegalovirus
(CMV) status, conditioning regimen (total-body irradiation
[TBI] vs. no TBI; etoposide vs. no etoposide), Karnofsky
score (‡ 90 vs. <90%), and time from diagnosis to transplant
( ‡ 1 vs. <1 year). A backward stepwise model building was
used to identify the covariates significantly associated with
the outcomes. The main effect (clinical trial patients vs.
IBMTR matched controls) was in all the models. The
assumption of proportional hazards over time was tested for
the main effects and all explanatory covariates, using a time-
dependent covariate. Nonproportional hazards were
addressed by using time-dependent covariates. The relative
risk (with 95% confidence interval and p value) of death was
calculated based on the final Cox regression model. The
Kaplan-Meier estimator was used to calculate and plot the
probability of survival and acute GVHD. A stratified log-
rank test was used for univariate comparisons [11].
RESULTS
Matching of clinical trial patients and IBMTR controls
Two controls matched for disease, pretransplant disease
status, and age were found for 100 of the 116 advanced-dis-
ease patients in the clinical trial. The demographic, disease-
related, and transplant-related characteristics of the
advanced-disease patients in the clinical trial and their
matched IBMTR controls are summarized in Table 2. 
Sixteen patients in the clinical trial (six tacrolimus, 10
cyclosporine) could not be matched with two controls (11
patients had no match, five patients had one match). Removal
of the 16 unmatched patients did not alter the survival pattern
differences between the two treatment arms. Survival without
(vs. with) the 16 patients was 27% (vs. 25%) in the tacrolimus
arm and 42% (vs. 42%) in the cyclosporine group. 
Two-year survival
Table 3 and Figs. 1–4 show Kaplan-Meier survival esti-
mates for the four study groups. Figure 1 compares the sur-
vival curve for the 100 advanced-stage disease clinical trial
patients with that of their 200 matched IBMTR controls.
Two-year survival probabilities were 33% for clinical trial
patients vs. 32% for their matched IBMTR controls. Sur-
vival of the 62 tacrolimus-treated clinical trial patients and
their 124 matched cyclosporine-treated IBMTR controls
was similar (Fig. 2), as was survival of the 38 cyclosporine-
treated clinical trial patients and their 76 cyclosporine-treat-
ed matched IBMTR controls (Fig. 3). Further, cyclosporine-
treated IBMTR controls matched to cyclosporine-treated
clinical trial patients showed significantly higher survival
than did cyclosporine-treated IBMTR controls matched to
clinical trial patients receiving tacrolimus (p < 0.01, log-rank
test) (Fig. 4).
Table 3 also shows risk ratios for 2-year mortality.
Matched controls selected from the IBMTR database show
a risk for death similar to that of their counterparts in the
two treatment arms of the clinical trial. However, the risk of
death for the IBMTR cyclosporine-treated patients matched
to tacrolimus-treated patients in the clinical trial is signifi-
cantly higher than that for IBMTR cyclosporine-treated
Table 1. IBMTR database used to select matched controls for clinical trial
participants
Criteria Number of patients
Same baseline diseases 15,443
Year of transplant 1990–1995 11,083
Age 15–60 years 9239
HLA-identical sibling donor 6878
Cyclosporine + methotrexate for GVHD prophylaxis 4562
North American transplant center 1448
Follow-up time ‡ 210 days* 1386
No overlap with the clinical trial 1381
No CML in chronic or accelerated phase 891
Pretransplant disease status known 879
*Includes all patients dying before day 210 posttransplant.
Table 2. Characteristics of advanced-disease* patients in the clinical trial and
their matched IBMTR controls
Clinical trial IBMTR
No. patients 100 200 
No. receiving GVHD prophylaxis
Tacrolimus and methotrexate 62 0 
Cyclosporine and methotrexate 38 200
Demographic characteristics
Median age (years) 40 40
(16–59) (15–59)
Male 58% 61%
Cytomegalovirus-positive 61% 56%
Karnofsky score >90% 42% 48%
Type of disease
Acute myeloid leukemia 32% 32%
Acute lymphoblastic leukemia 14% 14%
Chronic myelogenous leukemia 4% 4%
Chronic lymphocytic leukemia 2% 2%
Myelodysplastic syndrome 2% 2%
Non-Hodgkin’s lymphoma 21% 21%
Hodgkin’s disease 2% 2%
Multiple myeloma 23% 23%
Transplant-related variables
Female donor 43% 42%
Donor cytomegalovirus-positive 59% 54%
Conditioning regimen
Total-body irradiation 56% 51%
Busulfan + cyclophosphamide (cytoxan) 40% 47%
Etoposide 28% 37%
*Advanced-stage disease is defined as hematologic malignancy uncontrolled
(relapse or never in remission) at the time of transplantation or a type of
malignancy that, historically, has been associated with poor survival following
allogeneic bone marrow transplantation (e.g., multiple myeloma, chronic lym-
phocytic leukemia).
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patients matched to cyclosporine-treated patients in the
clinical trial (risk ratio 1.70; p < 0.01, Wald x2).
Grade II–IV acute GVHD
Consistent with the results of the primary study, patients
in the tacrolimus arm had a lower incidence of GVHD (p <
0.01, stratified log-rank test), with a relative risk of GVHD of
0.39 (Table 4). In contrast, the incidence of GVHD for cyclo-
sporine-treated IBMTR controls matched for the tacrolimus
arm was not different from that for cyclosporine-treated
IBMTR controls matched for the cyclosporine arm (Table 4).
DISCUSSION
In a randomized clinical trial of GVHD prophylaxis
regimens for HLA-identical marrow transplantation for
hematologic malignancies [1], overall 2-year Kaplan-Meier
survival estimates were 47% in the tacrolimus group and
57% in the cyclosporine group (p < 0.02, Wilcoxon test for
the equality of survival curves). This survival difference
resulted from a greater number of deaths in patients with
advanced disease in the tacrolimus group (51/68, 75%) com-
pared with the cyclosporine group (28/48, 58%), an effect
not expected from results of previous trials. A lower than
expected number of early deaths caused by recognized
transplant regimen–related toxicity (e.g., veno-occlusive dis-
ease, pulmonary toxicity, organ failure), infection, and
relapse of malignancy was observed in the advanced disease
patients in the cyclosporine group (10%), suggesting that
this group may have had a better prognosis at baseline than
did the tacrolimus-treated group, but no conclusive evi-
dence was provided by the clinical trial data. No single fac-
tor or interaction of any single factor with GVHD prophy-
laxis explained the result. The eligibility criteria of the trial
Table 3. Probability of 2-year survival and relative risk of death for advanced-disease patients in the clinical trial vs. their matched IBMTR controls
Comparison between designated groups
Probability of 2-year survival* Relative risk of death† 95% CI p value†
All clinical trial patients 33%
1.11 0.79–1.58 0.55
All cyclosporine-treated matched IBMTR controls 32%
Tacrolimus-treated clinical trial patients 27%
1.16 0.74–1.81 0.51
Cyclosporine-treated, tacrolimus-matched IBMTR controls 24%
Cyclosporine-treated clinical trial patients 42%
1.14 0.63–2.08 0.66
Cyclosporine-treated, cyclosporine-matched IBMTR controls 45%
Cyclosporine-treated, tacrolimus-matched IBMTR controls 24%
1.70 1.17–2.46 <0.01
Cyclosporine-treated, cyclosporine-matched IBMTR controls 45%
CI, confidence interval.
*Kaplan-Meier estimates.
†Cox model, Wald x2.
Figure 1. Two-year survival for all advanced-disease patients in the clinical trial vs. that of their matched IBMTR controls
All IBMTR patients were treated with cyclosporine. Survival patterns were comparable based on stratified log-rank test (p = 0.55).
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permitted a heterogeneous patient population and some dis-
eases that are not common indications for allogeneic trans-
plantation. Finding comparable groups in the published lit-
erature was not possible.
In the present study, the large clinical database main-
tained by the IBMTR was used to compare the survival of
patients in the clinical trial with that of matched controls, all
of whom received cyclosporine and methotrexate for
GVHD prophylaxis, to assess the prognosis of the two clini-
cal trial groups. The hypothesis was that if patients in the
two arms of the trial had inherently different prognoses
regardless of GVHD prophylaxis, then groups formed by
similarly treated matched controls for each arm would also
have different survival despite receiving the same GVHD
prophylaxis. This was confirmed in both Kaplan-Meier and
Cox regression analyses (Table 3), in which patients
matched to those in the tacrolimus arm of the clinical trial
had lower survival than did patients matched to the cyclo-
Figure 2. Two-year survival for tacrolimus-treated, advanced-disease patients in the clinical trial vs. that of their matched IBMTR controls
All IBMTR patients were treated with cyclosporine. Survival patterns were comparable based on stratified log-rank test (p = 0.51).
Figure 3. Two-year survival for cyclosporine-treated, advanced-disease patients in the clinical trial vs. that of their matched IBMTR con-
trols
All IBMTR patients were treated with cyclosporine. Survival patterns were comparable based on stratified log-rank test (p = 0.88).
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sporine arm, even though all of the matched controls
received cyclosporine-based GVHD prophylaxis.
The primary clinical trial comparing tacrolimus with
cyclosporine showed a lower incidence of grade II–IV acute
GVHD for tacrolimus-treated patients compared with
cyclosporine-treated patients. This was true for all patients
(32 vs. 44%) and for advanced disease patients (31 vs. 54%).
Interestingly, comparison of the two cyclosporine-treated
matched control groups showed no difference in the inci-
dence of GVHD. Thus, diagnosis and disease stage had an
impact on survival but not on the risk of GVHD. 
The randomized clinical trial is a powerful tool for mak-
ing unbiased assessments of treatment effects. Its use is
based on the assumption that randomization is the method
most likely to produce groups that are similar in their mea-
surable and unmeasurable baseline characteristics. Stratifica-
tion helps to ensure such comparability for characteristics
known to be important for prognosis. Occasionally, howev-
er, despite random assignment and stratification, treatment
groups are disparate for one or more factors that may con-
found an outcome of interest or produce an outcome unex-
pected from prior studies. This may occur when factors that
Figure 4. Two-year survival for IBMTR patients treated with cyclosporine and matched to advanced-disease patients in the clinical trial
treated with tacrolimus or cyclosporine
Cyclosporine-treated IBMTR patients matched to tacrolimus-treated clinical trial patients had a lower survival than did those matched to cyclosporine-treated clin-
ical trial patients based on log-rank test (p < 0.01).
Table 4. 
Grades II to IV acute GVHD within 100 days posttransplant
Comparison between designated groups
Grade II–IV acute GVHD* Relative risk† 95% CI p value†
All clinical trial patients 42%
0.73 0.46–1.18 0.20
All cyclosporine-treated matched IBMTR controls 48%
Tacrolimus-treated clinical trial patients 28%
0.39 0.19–0.81 0.01
Cyclosporine-treated, tacrolimus-matched IBMTR controls 50%
Cyclosporine-treated clinical trial patients 58%
1.59 0.79–3.21 0.19
Cyclosporine-treated, cyclosporine-matched IBMTR controls 45%
Cyclosporine-treated, tacrolimus-matched IBMTR controls 50%
1.10 0.71–1.71 0.67
Cyclosporine-treated, cyclosporine-matched IBMTR controls 45%
The same standard GVHD grading system was used for all groups.
*Kaplan-Meier estimates.
†Cox model, Wald x2.
CI, confidence interval.
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affect the primary efficacy endpoint differ from those affect-
ing an important safety endpoint. 
Herein, we have found that differences in the combina-
tion of diagnosis, pretransplant disease status, and age
between the two treatment arms within the advanced disease
group of patients confounded the analysis of survival. It is
not yet clear which specific combination of these factors
resulted in the imbalance in the mortality risk between the
two treatment arms. The results of the clinical trial and this
matched control study underscore the importance of incor-
porating stratification for potential risk factors affecting sur-
vival (e.g., disease diagnosis and disease status) into the
design of studies evaluating agents for the prophylaxis of
GVHD.
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